脓毒症诱导的内皮功能障碍通过血管生成素-2-HGF-C/EBPβ通路驱动慢加急性肝衰竭
该研究利用硫代乙酰胺联合盲肠结扎穿刺建立脓毒症相关慢加急性肝衰竭小鼠模型,发现肝细胞CCAAT增强子结合蛋白β(C/EBPβ)转录活性增加与肝合成功能下降和高死亡率相关;在人类慢加急性肝衰竭组中C/EBPβ染色质结合同样增加。内皮功能障碍表现为血管生成素-1/血管生成素-2比值降低和内皮HGF产生增加,补充血管生成素-1或敲低Hgf可减少肝细胞C/EBPβ积聚、恢复肝功能并降低死亡率。
要点
- 硫代乙酰胺联合盲肠结扎穿刺小鼠出现肝合成功能显著下降和高死亡率。
- 肝细胞特异性Cebpb敲除可降低硫代乙酰胺/盲肠结扎穿刺小鼠死亡率并增加肝细胞分化标志物基因表达。
- 补充血管生成素-1或敲低Hgf可减少肝细胞C/EBPβ积聚、恢复肝功能并降低死亡率。
核心结论
- 转录因子C/EBPβ在小鼠和人类慢加急性肝衰竭中均被激活,是预防脓毒症合并肝硬化患者肝衰竭的潜在治疗靶点。
研究设计与样本
- 研究采用经硫代乙酰胺处理的小鼠行盲肠结扎穿刺术诱导脓毒症相关慢加急性肝衰竭的新型小鼠模型,并比较人类慢加急性肝衰竭组与对照肝硬化组的C/EBPβ染色质结合。
主要发现
- 硫代乙酰胺联合盲肠结扎穿刺导致肝合成功能显著下降和高死亡率,伴代谢基因表达降低和C/EBPβ转录活性增加。
- C/EBPβ与其靶基因启动子的结合增加;人类慢加急性肝衰竭组C/EBPβ染色质结合较对照肝硬化组同样增加。
- 肝细胞特异性Cebpb敲除小鼠在硫代乙酰胺/盲肠结扎穿刺后死亡率降低,肝细胞分化标志物基因表达增加。
- C/EBPβ激活与内皮功能障碍相关,表现为血管生成素-1/血管生成素-2比值降低和内皮HGF产生增加。
- 补充血管生成素-1或敲低Hgf可减少肝细胞C/EBPβ积聚、恢复肝功能并降低死亡率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Acute-on-chronic liver failure (ACLF) is an acute liver and multisystem failure in patients with previously stable cirrhosis. A common cause of ACLF is sepsis secondary to bacterial infection. Sepsis-associated ACLF involves a loss of differentiated liver function in the absence of direct liver injury, and its mechanism is unknown. We aimed to study the mechanism of sepsis-associated ACLF using a novel mouse model. APPROACH AND RESULTS: Sepsis-associated ACLF was induced by cecal ligation and puncture procedure (CLP) in mice treated with thioacetamide (TAA). The combination of TAA and CLP resulted in a significant decrease in liver synthetic function and high mortality. These changes were associated with reduced metabolic gene expression and increased CCAAT enhancer binding protein beta (C/EBPβ) transcriptional activity. We found that C/EBPβ binding to its target gene promoters was increased. In humans, C/EBPβ chromatin binding was similarly increased in the ACLF group compared with control cirrhosis. Hepatocyte-specific Cebpb knockout mice had reduced mortality and increased gene expression of hepatocyte differentiation markers in TAA/CLP mice, suggesting that C/EBPβ promotes liver failure in these mice. C/EBPβ activation was associated with endothelial dysfunction, characterized by reduced Angiopoietin-1/Angiopoietin-2 ratio and increased endothelial production of HGF. Angiopoietin-1 supplementation or Hgf knockdown reduced hepatocyte C/EBPβ accumulation, restored liver function, and reduced mortality, suggesting that endothelial dysfunction induced by sepsis drives ACLF through HGF-C/EBPβ pathway. CONCLUSIONS: The transcription factor C/EBPβ is activated in both mouse and human ACLF and is a potential therapeutic target to prevent liver failure in patients with sepsis and cirrhosis.
引用
- Elias G, Schonfeld M, Saleh S, et al. Sepsis-induced endothelial dysfunction drives acute-on-chronic liver failure through Angiopoietin-2-HGF-C/EBPβ pathway. Hepatology. 2023. PMID: 36943063. doi:10.1097/HEP.0000000000000354
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。